Her expertise has been tapped by The Washington Post, CNN International, Time Magazine, Yahoo News, and many other media outlets (including Plant Based)
Naslund E, Gryback P, Backman K, et al
Parkinsons disease, characterized by dopaminergic neuronal loss in the substantia nigra leading to motor and non-motor symptoms, has also been linked to insulin resistance and impaired cerebral insulin signaling.128 GLP-1RAs and GLP-1/GIP dual-receptor agonists have demonstrated the capacity to enhance insulin sensitivity and exert antioxidant and anti-inflammatory effects in the brain.129 Preclinical studies in various PD animal models indicate that GLP-1RAs such as liraglutide, semaglutide, and lixisenatide promote dopamine synthesis and elevate striatal dopamine levels, thereby conferring neuroprotection to dopaminergic neurons.130132 The dual agonist telpor similarly exhibits neuroprotective effects by improving energy metabolism and inhibiting inflammatory pathways in PD models.126 Clinical trials have assessed the efficacy and safety of GLP-1RAs in PD patients with PD
Read clinical review Ozempic (semaglutide) lowers fasting glucose by 1.2 to 2.8 mmol/L in type 2 diabetes
*Correspondence: Yan Li, [email protected] These authors share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Glycemic targets: standards of medical care in diabetes-2020